ArticleDiabetology & metabolic syndrome2026
Metformin versus DPP-4 inhibitors and risk of parkinsonism in type 2 diabetes: an active-comparator cohort study with a landmark design.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a significant risk factor for Parkinson's disease (PD). While metformin shows neuroprotective potential in preclinical models, clinical evidence remains conflicting, likely due to limited follow-up, comparator heterogeneity, and insufficient consideration of differential survival.
methodsWe conducted a retrospective cohort study (observing data from 2005 to 2025) using the TriNetX global network. Using an incident user design and a 1-year landmark period to ensure sustained therapy and minimize immortal time bias, we matched 75,535 metformin initiators with 75,535 dipeptidyl peptidase-4 inhibitor (DPP-4i) users via propensity scores. The primary outcome was a composite of new-onset idiopathic PD and secondary parkinsonism. Exploratory time-stratified landmark analyses assessed whether the association differed among patients alive and outcome-free at 5 and 10 years.
resultsFollowing the landmark period, over a median follow-up of 5.2 years (IQR, 2.8-8.4; total 785,564 person-years), the overall risk of the composite neurologic outcome was similar between groups (aHR, 0.97; 95% CI, 0.87-1.09). Metformin users had lower observed all-cause mortality than DPP-4 inhibitor users (aHR, 0.75; 95% CI, 0.73-0.77). In a 5-year landmark sensitivity analysis, no association was observed (aHR, 0.98; 95% CI, 0.88-1.09). In exploratory analyses, a lower observed risk was seen among individuals surviving beyond 10 years (aHR, 0.85; 95% CI, 0.75-0.97; p = 0.0152), but this analysis was conditioned on long-term survival and should be interpreted as exploratory and hypothesis-generating.
conclusionsThe primary analysis showed no overall difference in parkinsonism risk. Metformin users had lower observed all-cause mortality, which may reflect residual confounding or treatment-selection mechanisms. The lower observed parkinsonism risk among patients surviving beyond 10 years was exploratory and hypothesis-generating, and may be affected by survivor or collider bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.